Advances in Chimeric Antigen Receptor T Cell Therapy in Neuroimmune Diseases

Antibody therapy is a crucial modality for the treatment of neuroimmune diseases.While it can regulate disease activity in the majority of patients,several individuals remain unresponsive to antibody therapy;additionally,the blood-brain barrier restricts the bioavailability and effectiveness of antibodies within the central nervous system.Unlike antibody therapies,emerging chimeric antigen receptor(CAR)-T cell therapies integrate the biological functions of antibodies that target specific molecules with the potent immune capabilities of T cells,resulting in enhanced therapeutic efficacy,improved tissue permeability,and a more pronounced capacity to eliminate target cells.This study encapsulated the advancements in CAR-T cell therapy for neuroimmune illnesses,aiming to furnish novel insights for the enhancement of CAR-T cell therapy to facilitate its practical use.